Solid Biosciences Announces Oversubscribed $240 Million Private Placement

Core Viewpoint - Solid Biosciences Inc. has announced a private placement of approximately $240 million with institutional accredited investors to support its development of precision genetic medicines for neuromuscular and cardiac diseases [1][3]. Group 1: Private Placement Details - The company is selling 14,973,257 shares of common stock at a price of $5.61 per share, along with pre-funded warrants to purchase up to 27,807,482 shares at a price of $5.609 per warrant [2]. - The private placement is expected to close on or about March 9, 2026, subject to customary closing conditions [1]. Group 2: Use of Proceeds - Net proceeds from the private placement will be used to fund ongoing pipeline development programs, business development activities, and for working capital and other general corporate purposes [3]. Group 3: Investors and Agents - The private placement is anchored by existing and new investors, including Perceptive Advisors, Bain Capital Life Sciences, and RA Capital Management [3]. - Leerink Partners and Citigroup are acting as joint lead placement agents, with Cantor as co-lead placement agent [4]. Group 4: Company Overview - Solid Biosciences focuses on advancing gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy and Friedreich's ataxia [7]. - The company aims to improve the daily lives of patients living with devastating rare diseases through innovative genetic medicines [7].